Salt Lake City, Utah (PRWEB) May 22, 2014
Co-Diagnostics, Inc.’s groundbreaking Cooperative Primers technology, developed by its CTO, Dr. Brent Satterfield, is now officially available to license to laboratories and research facilities worldwide.
The innovation of the patent-pending Cooperative Primers technology lies in its ability to prevent the “primer-dimer” phenomenon in real-time PCR testing. “Primer-dimers” can create any number of false-negatives and false-positives, leading to decreased specificity and sensitivity of real-time PCR testing platforms and inaccurate diagnoses. Not only does this technology prevent the occurrence of “primer-dimers,” but it also increases the specificity of PCR tests by more than 2.5 million times. Included with its introduction in the March 2014 issue of The Journal of Molecular Diagnostics was a technical commentary requested by The Journal. In this commentary, leading industry experts noted that Cooperative Primers adds “a power tool to the PCR toolkit” to prevent previously unrecognized, sporadic false-negative results.
Co-Diagnostics CEO Dwight Egan commented, “We have always believed that Co-Diagnostics was on the forefront of innovative real-time PCR solutions, and the validation that Cooperative Primers technology has received from the scientific world substantiates that belief. The release of this technology will allow the rest of the world the opportunity to participate in low-cost and highly sensitive real-time PCR technologies, while at the same time creating an exciting value proposition for Co-Diagnostics and our shareholders.”
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.